Subscribe
shutterstock_1953872293_marlon_trottmann
Marlon Trottmann / Shutterstock.com
7 November 2022AmericasStaff Writer

SCOTUS agrees to hear Amgen revival bid

The dispute centres on a section of the Patent Act concerning 'enablement' | The US government had urged the court to deny the petition.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
SCOTUS rejects BMS vs Gilead patent clash
10 November 2022   Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.


Editor's picks

Latham steps into dispute over $6bn treatment, replacing Kirkland
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

Editor's picks

Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Africa
Explainer: ARIPO’s role in Plant Variety Protection
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025

More on this story

Big Pharma
SCOTUS rejects BMS vs Gilead patent clash
10 November 2022   Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

More on this story

Big Pharma
SCOTUS rejects BMS vs Gilead patent clash
10 November 2022   Dispute over patent relating to a CAR-T cell therapy shunned by top court | Backing from Amgen, GSK and St. Jude's Children's Research Hospital over “exceedingly narrow” patent protection fails to convince Justices.
Americas
Fed Circ invaded jury’s role in Repatha case, says Amgen
25 November 2021   Amgen has urged the US Supreme Court to wade into its legal wrangle with Sanofi and Regeneron Pharmaceuticals over patents covering a cholesterol drug, Repatha.

More features

Judge overturns Amgen’s $50m damages loss
Weil adds two more litigators from larger rival
Why the PTAB’s new expedited filing dates for AIA petitions is positive
Ninth Circuit revives trade secrets claims in DNA-sequencing spat
Latham steps into dispute over $6bn treatment, replacing Kirkland
Patent pollution: Emissions charter aims to clean up IP
Why Trump’s revenue-raising patent plan is riddled with problems
Harvard’s patent portfolio at risk as Trump turns up the pressure